Correction of Notice of Time of Greenbrook TMS Second Quarter 2023 Financial Results
August 14 2023 - 8:55AM
Business Wire
Greenbrook TMS Inc. (NASDAQ: GBNH) (“Greenbrook” or the
“Company”), announced a correction to its press release
originally dated August 9, 2023 announcing the release of its
operational and financial results for the second quarter 2023.
In the original press release, the operational and financial
results for the second quarter 2023 were stated to be released
after market hours on August 15, 2023. Instead, the correct timing
of the release will be after market hours on August 14, 2023.
SECOND QUARTER 2023 CONFERENCE CALL DETAILS:
Bill Leonard, President and Chief Executive Officer, and Erns
Loubser, Chief Financial Officer, will host a conference call at
10:00 a.m. (Eastern Time) on August 15, 2023 to discuss the
financial results for the quarter.
Dial in Numbers:
Toll Free North America: 1 (888) 886-7786 Toronto: (416)
764-8658
Webcast:
For more information or to listen to the call via webcast,
please visit: www.greenbrooktms.com/investors/events.htm
For those that plan on accessing the conference call or webcast,
please allow ample time prior to the call time.
Conference Call Replay:
Following the live call, a replay will be available on the
Investor Relations section of the Company’s website,
www.greenbrooktms.com/investors/events.htm
About Greenbrook TMS Inc.
Operating through 133 Company-operated treatment centers,
Greenbrook is a leading provider of Transcranial Magnetic
Stimulation (“TMS”) and Spravato® (esketamine nasal spray),
FDA-cleared, non-invasive therapies for the treatment of Major
Depressive Disorder (“MDD”) and other mental health
disorders, in the United States. TMS therapy provides local
electromagnetic stimulation to specific brain regions known to be
directly associated with mood regulation. Spravato® is offered to
treat adults with treatment-resistant depression and depressive
symptoms in adults with MDD with suicidal thoughts or actions.
Greenbrook has provided more than one million treatments to over
32,000 patients struggling with depression.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20230814097856/en/
For further information:
Glen Akselrod Investor Relations Greenbrook TMS Inc.
investorrelations@greenbrooktms.com 1-855-797-4867
Greenbrook TMS (NASDAQ:GBNH)
Historical Stock Chart
From Sep 2024 to Oct 2024
Greenbrook TMS (NASDAQ:GBNH)
Historical Stock Chart
From Oct 2023 to Oct 2024